Related Experiment Video
Updated: Aug 6, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
XunZi, an AI biologist, reveals disease-modifying targets
Xinhe Huang1, Junhong Qin2, Fei Tang3
1Key Laboratory of Molecular Biophysics of Ministry of Education, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
None:
Hypothesis generation in biomedicine is constrained by human cognitive limitations in synthesizing insights from fragmented biomedical knowledge and multimodal data sources. Here we introduce XunZi, an AI biologist that integrates logical reasoning and multimodal data fusion to autonomously generate de novo therapeutic target hypotheses with testable mechanisms. XunZi has been trained on 24.4 million publications and 613.6 TB of multisource data spanning 21,008 human genes and 5,850 diseases, and outperforms existing methods in both accuracy and interpretability across diverse disease contexts. In Parkinson's disease (PD), where complex mechanisms and limited targets hamper therapy development, XunZi identifies aberrant activation of CHK2 and IRAK4 kinases across multiple models. Pharmacological or genetic inhibition of Chk2 rescues dopaminergic neuron loss and motor deficits in PD mice. We further demonstrate XunZi's broad versatility in diseases such as non-small-cell lung cancer. XunZi establishes a paradigm-shifting framework to translate fragmented biomedical knowledge and data into actionable therapeutics.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
